Nima Farzan, Kinnate CEO
Kinnate gets $98M Series C to push precision oncology drugs to the clinic
Less than a year after banking $74.5 million in a Series B, San Diego-based Kinnate Biopharma is following up with a Series C to bring its pipeline of precision oncology drugs to the clinic.
The two-year-old company just raised $98 million in a round led by RA Capital Management, and is eyeing INDs for its two lead programs — kinase inhibitors that target BRAF, FGFR2 and FGFR3 mutations. If all goes well in preclinical studies, CEO Nima Farzan expects its BRAF program to enter Phase I in the first half of next year, with its FGFR program not far behind.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters